Yamanaka may have found a way to give exogenous Myc the boot from the iPS cell universe. It has always been a frustration in the iPS cell field that Myc, a proto-oncogene, is so important for reprogramming. Yes, you can make iPS cells (especially mouse) without Myc, but it can be orders of magnitude harder, […]
New iPS cell method: drop Myc or not yet? Read More »
The best talk today was the keynote address by Dr. George Daley focused mostly on iPS cells. Dr. Daley is one of the world’s experts on iPS cells and pluripotent stem cells more generally. He covered many interesting elements of the iPS cell field including the genetic mutations that seem to occur during the reprogramming
Summary of George Daley talk on iPS cells today in Seattle Read More »
There were three talks today on iPS cells here at the American Society for Gene and Cell Therapy meeting or ASGCT meeting in Seattle. Dr. James Ellis made the interesting case that it may be preferable to make iPS cells using genetic methods (while everyone else seems to be saying that non-genetic methods will be better).
News on iPS cells from some top scientists at ASGCT meeting today Read More »
Today is Friday the 13th, which is supposed to be bad luck, and it seems to be a bad luck day for iPS cells. A paper came out today in Nature that will be highly upsetting for anyone hoping that iPS cells can follow a fairly direct path to the clinic. The paper from Yang
Friday the 13th for iPS cells Read More »
Yesterday I ran a cancer stem cells meeting here at UC Davis School of Medicine. We had some great speakers and over 150 participants including our outstanding keynote speaker, Dr. Jeremy Rich, Director of Stem Cell Research at the Cleveland Clinic. One of the ideas percolating through the meeting was that during cancer development, there
Cancer stem cells and iPS cells Read More »
Since Yamanaka’s discovery of iPS cells first in mouse and then in human cells 5 years ago, both made using viral transduction, a host of new methods to make iPS cells have been reported. These methods are quite diverse, ranging from transposons, to recombinant proteins, to plasmids, and to RNA. Often times these new approaches
Why miRNA iPS cells might be the ticket: an A+ paper Read More »
Who’s who in the field of iPS cells? In this post, I examine the people, journals, places, funding agencies, and companies that are the leaders in the iPS cell field. I start with publishing. Last year we did a post on publishing trends in the iPS cell field. It suggested that the iPS cell field was
Who’s who in iPS cells: scientists, journals, funding agencies, countries, and biotechs Read More »
What are iPS cells? We talk about iPS cells all the time. We are very excited about them. Heck, the web address for this blog is ipscell.com. But what are iPSCs, really? iPS cells definition A simple definition of iPSCs is the following: Embryonic stem cell-like cells that are made from non-stem cells in a
An insider’s guide: what are iPS cells? Read More »
What is RNA-based iPS cell research? It was only six months ago that the stem cell field was aflutter over the report by the Rossi group that they could reprogram iPS cells with an astonishingly high efficiency using just RNAs. This completely non-genetic, high-efficiency approach seemed like a revolution for the iPS cell field. It
Is RNA-based iPS cell production a flash in the pan/tissue culture dish? Read More »
A group of researchers led by Evan Snyder (paper discussed here) published a paper in PNAS on a new type of neural stem-like cell whose pluripotency can be turned ON or OFF by turning the v-myc gene ON or OFF using a conditional system of expression, called a “Tet-ON” system. In this system, tetracycline or its
“Alternative” to IPS cells, ICSP, are very cool, but for now a no-go for the FDA Read More »